open access publication

Article, 2014

Magnetic Resonance Image Guided Brachytherapy

Seminars in Radiation Oncology, ISSN 1532-9461, 1053-4296, Volume 24, 3, Pages 181-191, 10.1016/j.semradonc.2014.02.007

Contributors

Tanderup, Kari 0000-0001-7980-0681 (Corresponding author) [1] [2] Viswanathan, Akila Ninette 0000-0002-2003-0392 [3] Kirisits, Christian 0000-0002-2815-8083 [4] Frank, Steven Jay 0000-0001-6517-7884 [5]

Affiliations

  1. [1] Aarhus University Hospital
    2. [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  2. [2] Washington University in St. Louis
    3. [NORA names: United States; America, North; OECD];
  3. [3] Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women׳s Hospital, Boston, MA
    4. [NORA names: United States; America, North; OECD];
  4. [4] Medical University of Vienna
    5. [NORA names: Austria; Europe, EU; OECD];
  5. [5] The University of Texas MD Anderson Cancer Center
    6. [NORA names: United States; America, North; OECD]

Abstract

The application of magnetic resonance image (MRI)-guided brachytherapy has demonstrated significant growth during the past 2 decades. Clinical improvements in cervix cancer outcomes have been linked to the application of repeated MRI for identification of residual tumor volumes during radiotherapy. This has changed clinical practice in the direction of individualized dose administration, and resulted in mounting evidence of improved clinical outcome regarding local control, overall survival as well as morbidity. MRI-guided prostate high-dose-rate and low-dose-rate brachytherapies have improved the accuracy of target and organs-at-risk delineation, and the potential exists for improved dose prescription and reporting for the prostate gland and organs at risk. Furthermore, MRI-guided prostate brachytherapy has significant potential to identify prostate subvolumes and dominant lesions to allow for dose administration reflecting the differential risk of recurrence. MRI-guided brachytherapy involves advanced imaging, target concepts, and dose planning. The key issue for safe dissemination and implementation of high-quality MRI-guided brachytherapy is establishment of qualified multidisciplinary teams and strategies for training and education.

Keywords

MRI, MRI-guided brachytherapy, MRI-guided prostate brachytherapy, Subvolume, accuracy, accuracy of targeting, administration, advanced imaging, applications, brachytherapy, cancer outcomes, cervix, clinical improvement, clinical outcomes, clinical practice, concept, control, decades, delineation, differential risk, direction, dissemination, dominant lesion, dose, dose administration, dose planning, dose prescription, education, evidence, gland, growth, guided brachytherapy, high-dose-rate, identification, image guided brachytherapy, images, implementation, improvement, issues, lesions, local control, low-dose-rate brachytherapy, magnetic resonance imaging (MRI)-guided brachytherapy, magnetization, morbidity, mounting evidence, multidisciplinary team, organization, organs-at-risk delineation, outcomes, overall survival, planning, potential, practice, prescription, prostate, prostate brachytherapy, prostate gland, prostate high-dose-rate, qualified multidisciplinary team, radiotherapy, recurrence, reports, residual tumor volume, risk, risk of recurrence, significant growth, strategies, survival, target, target concept, team, training, tumor volume, volume

Funders

  • National Cancer Institute
  • FWF Austrian Science Fund
  • Lundbeck Foundation
  • Danish Cancer Society
  • Innovation Fund Denmark

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+